@mejustasmallerversion's Wegovy day post, fact-checked

What does this video actually claim?

This TikTok doesn't make any specific medical claims. The creator @mejustasmallerversion simply shows their weekly Wegovy injection routine with hashtags about "pen day" and a "healthier me."

It's a straightforward documentation post rather than educational content. The creator uses standard GLP-1 injection hashtags but doesn't discuss dosing, side effects, or weight loss expectations.

While the video itself is innocuous, the hashtags connect it to the broader social media conversation about semaglutide for weight management.

Is weekly Wegovy injection the standard protocol?

Yes, Wegovy (semaglutide 2.4mg) is designed as a once-weekly subcutaneous injection. The STEP clinical trial program used this exact dosing schedule.

The STEP 1 trial (Wilding et al., NEJM, 2021) tested weekly semaglutide injections starting at 0.25mg and escalating over 16 weeks to the maintenance dose of 2.4mg. Participants achieved 14.9% average weight loss at 68 weeks.

The weekly schedule works because semaglutide has a half-life of about 7 days. This allows steady GLP-1 receptor activation while maintaining convenient dosing for patients.

What does the science say about Wegovy's effectiveness?

The clinical data for Wegovy is strong across multiple large trials. The STEP program enrolled over 4,500 participants and consistently showed substantial weight loss.

STEP 1 found 83.5% of participants lost at least 5% of their body weight, while 48.1% lost 15% or more. The STEP 3 trial (Wadden et al., NEJM, 2021) combined semaglutide with intensive behavioral therapy and achieved 16.0% average weight loss.

However, the STEP 4 trial (Rubino et al., NEJM, 2021) showed that stopping semaglutide led to significant weight regain. Participants regained 11.6 percentage points of their lost weight within 68 weeks of discontinuation.

What are the real risks this video doesn't mention?

The creator's casual "pen day" framing doesn't acknowledge Wegovy's substantial side effect profile. Most users experience gastrointestinal symptoms during the initial weeks.

In STEP 1, 74.2% of semaglutide users reported adverse events compared to 47.9% on placebo. Nausea affected 58.0% of participants, while 24.8% experienced vomiting and 29.8% had diarrhea.

More concerning, 7.0% of participants discontinued due to adverse events. The STEP trials also documented cases of gallbladder disease and acute pancreatitis, though these remained rare.

What should you actually know about Wegovy?

Wegovy represents genuine medical progress for obesity treatment, but it's not the casual lifestyle intervention that social media often portrays. The medication requires ongoing medical supervision and lifestyle changes.

The drug works by mimicking GLP-1, a hormone that slows gastric emptying and affects appetite regulation in the hypothalamus. This isn't simply appetite suppression but involves complex metabolic pathways.

Cost remains a major barrier. Wegovy's list price exceeds $1,300 monthly, and insurance coverage varies widely. The STEP trials were conducted under ideal conditions with significant medical support that may not reflect real-world use.